New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:12 EDTMYGN, TSROMyriad Genetics announces HRD collaboration with TESARO
Myriad Genetics (MYGN) announced that Tesaro (TSRO) will use Myriad's novel HRD, or homologous recombination deficiency, test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase, or PARP, inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
News For MYGN;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
07:14 EDTMYGNMyriad Genetics, AstraZeneca expand research collaboration on Lynparza
Subscribe for More Information
05:58 EDTTSROTESARO price target raised to $65 from $50 at Mizuho
Subscribe for More Information
March 30, 2015
10:52 EDTMYGNLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
March 26, 2015
10:04 EDTMYGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:07 EDTMYGNMyriad Genetics downgraded to Sell from Neutral at Goldman
Subscribe for More Information
March 20, 2015
07:41 EDTMYGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
05:17 EDTMYGNMyriad EMPATHY-P clinical study results to be highlighted at annual congress
Myriad Genetics announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods, which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use